BCL2 and hematologic disorder: Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins in the intrinsic apoptotic pathway is observed in hematologic malignancies; therefore, targeting the apoptotic pathways like the regulatory BCL-2 family in the intrinsic pathway is an important therapeutic approach in these patients [158,159,160].